Twice As Nice: Seattle Genetics, Merck & Co. Partner On Two Cancer Drugs
Companies Will Jointly Develop A Novel ADC And Commercialize Tukysa
Merck & Co. will pay Seattle Genetics $725m up front in cash under the two deals and make a $1bn equity investment in the company, providing financial flexibility to broadly fund the pipeline.
You may also be interested in...
The US firm gets development and co-commercial rights to MORAb-202 for $650m up front. BMS joins AstraZeneca, Merck & Co. and Gilead in recent ADC deal-making.
Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.
The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.